Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 730 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Observational study only Clear all
Terminated Not applicable Interventional

Severe OSA Study (SOS)

NCT05445869
View directory record Official record
Conditions
Obstructive Sleep Apnea, Sleep Apnea
Interventions
ProSomnus® EVO Sleep and Snore Device
Device
Lead sponsor
ProSomnus Sleep Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Redwood City, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 30, 2026, 5:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficiency of Task Switching and Multi-tasking

NCT03685266
View directory record Official record
Conditions
Task Performance and Analysis, Efficiency
Interventions
Observation
Other
Lead sponsor
University of Hawaii
Other
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 30, 2026, 5:48 AM EDT
Terminated Phase 4 Interventional Results available

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101
View directory record Official record
Conditions
HIV
Interventions
Raltegravir
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 30, 2026, 5:48 AM EDT
Not listed Phase 3 Interventional

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00719303
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Behavioral Dietary Intervention, Compliance Monitoring, Counseling, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
687
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 452 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 30, 2026, 5:48 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects on Sleep Quality of 1:4 Reishi Liquid Extract

NCT07294482
View directory record Official record
Conditions
Sleep
Interventions
Bristol Fungarium's 1:4 Reishi Mushroom Tincture
Dietary Supplement
Lead sponsor
Efforia, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 30, 2026, 5:48 AM EDT
Completed No phase listed Observational

Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology

NCT02847130
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Childhood Acute Myeloid Leukemia, Childhood Burkitt Lymphoma, Childhood Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
Informational Intervention, Interview, Medical Chart Review, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
31
States / cities
Oakland, California • Wilmington, Delaware • Fort Myers, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 30, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional Results available

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

NCT01349192
View directory record Official record
Conditions
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions
Rifampin, Trimethoprim/Sulfamethoxazole, Minocycline, Mupirocin, chlorhexidine gluconate oral rinse, 2% Chlorhexidine solution wipes, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Birmingham, Alabama • Aurora, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 30, 2026, 5:48 AM EDT
Terminated No phase listed Observational

Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery

NCT05591092
View directory record Official record
Conditions
Thyroid Gland Follicular Carcinoma
Interventions
Computed Tomography, Iodine I-123, Planar Imaging, Single Photon Emission Computed Tomography
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 5:48 AM EDT
Recruiting No phase listed Observational

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

NCT04517838
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 30, 2026, 5:48 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

A Comprehensive Optical Blood Pressure Assessment Tool to Identify Cases of Unscreened Hypertension Across an Active Population in the U.S.

NCT06721611
View directory record Official record
Conditions
Hypertension
Interventions
Optical Blood Pressure Monitoring Device (Aktiia G1)
Device
Lead sponsor
Nucor
Industry
Eligibility
25 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 30, 2026, 5:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy

NCT06240598
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Second Look Laparoscopy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 5:48 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Emotion Regulation and Burnout Impact on Communication Documentation

NCT03901547
View directory record Official record
Conditions
Communication
Interventions
Communication Skills Training, Profile feedback, Maslach burnout inventory, Emotion Regulation Skills Question (ERSQ), Semi-structured interview, Priming
Behavioral · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Observation of Perioperative Outcomes of Robotic Pancreaticoduodenectomy

NCT04171440
View directory record Official record
Conditions
Pancreaticoduodenectomy
Interventions
robotic pancreaticoduodenectomy
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 30, 2026, 5:48 AM EDT
Recruiting No phase listed Observational

Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections

NCT06775106
View directory record Official record
Conditions
Pulmonary Disease, Critical Illness
Interventions
There is no intervention in this observational study
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 30, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Results available

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

NCT04147234
View directory record Official record
Conditions
Neoplasms
Interventions
BI 1387446 50 μg, BI 754091, BI 1387446 100 μg, BI 1387446 200 μg, BI 1387446 400 μg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 30, 2026, 5:48 AM EDT
Active, not recruiting Not applicable Interventional

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

NCT05701358
View directory record Official record
Conditions
Acute Myocardial Infarction, Coronary Artery Disease
Interventions
Physiology-guided NCL PCI, Angiography-guided NCL PCI
Procedure
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
5,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 5:48 AM EDT
Completed Not applicable Interventional Results available

Arm Rehabilitation Study After Stroke

NCT00871715
View directory record Official record
Conditions
Stroke, Brain Infarction, Brain Ischemia, Cerebral Infarction, Cerebrovascular Disorders
Interventions
Accelerated Skill Acquisition Program (ASAP), Dose-Equivalent Usual & Customary Care - DEUCC, Usual and Customary Care - UCC
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
21 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 30, 2026, 5:48 AM EDT
Not listed No phase listed Observational

Malnutrition's Role in Fall Risk

NCT03011918
View directory record Official record
Conditions
Falling Injury, Nutrition Disorder
Interventions
Data Collection prior to first fall for all fallers, Hgb value, Vitamin D, C-Reactive Protein
Other
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 30, 2026, 5:48 AM EDT
Completed No phase listed Observational

COOL-ARREST Pilot Study to Assess Intravascular Temperature Management (IVTM) in the Treatment of Cardiac Arrest

NCT01818388
View directory record Official record
Conditions
Out of Hospital Cardiac Arrest
Interventions
ZOLL Intravascular Temperature Management System (IVTM)
Device
Lead sponsor
ZOLL Circulation, Inc., USA
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
New Britain, Connecticut • Detroit, Michigan • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 30, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 5:48 AM EDT
Completed No phase listed Observational

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

NCT00557180
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Beclomethasone dipropionate HFA, Tiotropium bromide, Salmeterol xinafoate
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 30, 2026, 5:48 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

NCT00198510
View directory record Official record
Conditions
Vitreous Hemorrhage, Diabetic Retinopathy
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
61
States / cities
Tucson, Arizona • Beverly Hills, California • Chula Vista, California + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 30, 2026, 5:48 AM EDT
Recruiting No phase listed Observational

Osteochondritis Dissecans of Knee Prospective Cohort

NCT02771496
View directory record Official record
Conditions
Osteochondritis Dissecans
Interventions
Other: observational only- no intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2074
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 30, 2026, 5:48 AM EDT
Completed No phase listed Observational

Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice

NCT04568083
View directory record Official record
Conditions
Myocardial Infarction (MI)
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Up to 130 Years
Enrollment
7,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 30, 2026, 5:48 AM EDT